
EU Approves Johnson & Johnson’s IMAAVY® (nipocalimab) for Broad gMG Patients, Enabling Long-Term Disease Control
Johnson & Johnson Secures European Commission Approval for IMAAVY® (nipocalimab)—A Groundbreaking FcRn Blocker for Generalised Myasthenia Gravis In a landmark development for the treatment of generalized myasthenia gravis (gMG), Johnson & Johnson IMAAVY has announced that the European Commission (EC)…











